WO2005025554A3 - Inhibiteur de la dipeptidylpeptidase iv - Google Patents

Inhibiteur de la dipeptidylpeptidase iv Download PDF

Info

Publication number
WO2005025554A3
WO2005025554A3 PCT/JP2004/013480 JP2004013480W WO2005025554A3 WO 2005025554 A3 WO2005025554 A3 WO 2005025554A3 JP 2004013480 W JP2004013480 W JP 2004013480W WO 2005025554 A3 WO2005025554 A3 WO 2005025554A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
dipeptidyl peptidase
dpp
stereoisomer
solvate
Prior art date
Application number
PCT/JP2004/013480
Other languages
English (en)
Other versions
WO2005025554A2 (fr
Inventor
Kazuhiro Tsutsumi
Hisashi Shinkai
Yuki Kitao
Masaki Yamashita
Satoru Kobayashi
Kenichi Matsui
Tomohiro Oda
Toshio Taniguchi
Kota Asahina
Original Assignee
Japan Tobacco Inc
Kazuhiro Tsutsumi
Hisashi Shinkai
Yuki Kitao
Masaki Yamashita
Satoru Kobayashi
Kenichi Matsui
Tomohiro Oda
Toshio Taniguchi
Kota Asahina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34317220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005025554(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc, Kazuhiro Tsutsumi, Hisashi Shinkai, Yuki Kitao, Masaki Yamashita, Satoru Kobayashi, Kenichi Matsui, Tomohiro Oda, Toshio Taniguchi, Kota Asahina filed Critical Japan Tobacco Inc
Publication of WO2005025554A2 publication Critical patent/WO2005025554A2/fr
Publication of WO2005025554A3 publication Critical patent/WO2005025554A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Selon l'invention, un composé de formule [I], dans laquelle chaque symbole est tel que défini dans la spécification, ou un stéréoisomère associé, un sel acceptable pharmaceutiquement ou un solvate associé présentent une activité inhibitrice de la dipeptidylpeptidase IV et constituent de nouveaux composés efficaces dans le traitement de diabètes de type II, de l'obésité et similaire.
PCT/JP2004/013480 2003-09-09 2004-09-09 Inhibiteur de la dipeptidylpeptidase iv WO2005025554A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2003-317407 2003-09-09
JP2003317407 2003-09-09
JP2003395879 2003-11-26
JP2003-395879 2003-11-26
JP2004-114685 2004-04-08
JP2004114685 2004-04-08

Publications (2)

Publication Number Publication Date
WO2005025554A2 WO2005025554A2 (fr) 2005-03-24
WO2005025554A3 true WO2005025554A3 (fr) 2005-07-28

Family

ID=34317220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/013480 WO2005025554A2 (fr) 2003-09-09 2004-09-09 Inhibiteur de la dipeptidylpeptidase iv

Country Status (4)

Country Link
AR (1) AR046330A1 (fr)
PE (1) PE20050948A1 (fr)
TW (1) TW200530157A (fr)
WO (1) WO2005025554A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP1871362A2 (fr) 2005-04-27 2008-01-02 Arena Pharmaceuticals, Inc. Polytherapie pour le traitement, d'une part, de l'obesite et de diabetes et des troubles associes et, d'autre part, de troubles ameliores par l'augmentation d'un niveau glp-1 sanguin
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
JP2009533393A (ja) 2006-04-12 2009-09-17 プロビオドルグ エージー 酵素阻害薬
EP2054051B1 (fr) * 2006-08-16 2013-02-27 Amderma Pharmaceuticals, Llc Utilisation de dérivés de 2,5-dihydroxybenzène pour le traitement de la kératose actinique
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
EP2091948B1 (fr) 2006-11-30 2012-04-18 Probiodrug AG Nouveaux inhibiteurs de glutaminylcyclase
EP2865670B1 (fr) 2007-04-18 2017-01-11 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
WO2009099763A1 (fr) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d’esters
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
JP5605844B2 (ja) 2008-10-17 2014-10-15 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP5890312B2 (ja) * 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
AU2011237775A1 (en) 2010-04-06 2012-11-22 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
EP2585102B1 (fr) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Promédicaments insuliniques à base d'amide
WO2012012642A1 (fr) 2010-07-22 2012-01-26 Zafgen Corporation Composés tricycliques et procédés pour les préparer et les utiliser
CN103539791B (zh) 2010-09-22 2017-01-11 艾尼纳制药公司 Gpr119 受体调节剂和对与其相关的障碍的治疗
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
WO2012119941A1 (fr) 2011-03-04 2012-09-13 Prozymex A/S Composés de peptidylnitrile à titre d'inhibiteurs de peptidases
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (fr) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2013109739A1 (fr) 2012-01-18 2013-07-25 Zafgen, Inc. Composés sulfonamides tricycliques, procédés de fabrication et d'utilisation de ceux-ci
MX2014008705A (es) 2012-01-18 2015-02-05 Zafgen Inc Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
CA2890344A1 (fr) 2012-11-05 2014-05-08 Zafgen, Inc. Composes tricycliques a utiliser dans le traitement et/ou la lutte contre l'obesite
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
KR20150079952A (ko) 2012-11-05 2015-07-08 자프겐 인크. 트리시클릭 화합물 및 그의 제조 및 사용 방법
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
CA2964276A1 (fr) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Agents immunoregulateurs
HRP20211877T1 (hr) 2014-12-17 2022-03-04 Pimco 2664 Limited Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
JP7132125B2 (ja) * 2016-04-04 2022-09-06 リサーチ トライアングル インスティテュート ニューロペプチドｓ受容体（ｎｐｓｒ）アゴニスト
EP3582772A1 (fr) 2017-02-16 2019-12-25 Arena Pharmaceuticals, Inc. Composés et méthodes de traitement de l'angiocholite biliaire primitive
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
US10683267B1 (en) * 2019-11-21 2020-06-16 King Abdulaziz University Antidiabetic compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006074A1 (fr) * 1994-08-20 1996-02-29 British Biotech Pharmaceuticals Limited Inhibiteurs de metalloproteinases
WO1998045330A1 (fr) * 1997-04-04 1998-10-15 Medivir Ab Inhibiteurs de proteases antiviraux
WO2000034241A1 (fr) * 1998-12-10 2000-06-15 Novartis Ag 2-cyanopyrrolidines n-substitues
WO2003029200A2 (fr) * 2001-10-02 2003-04-10 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles comme inhibiteurs reversibles de cysteine protease
WO2003045977A2 (fr) * 2001-11-26 2003-06-05 Trustees Of Tufts College Inhibiteurs peptidomimetiques d'enzymes de clivage post-proline

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006074A1 (fr) * 1994-08-20 1996-02-29 British Biotech Pharmaceuticals Limited Inhibiteurs de metalloproteinases
WO1998045330A1 (fr) * 1997-04-04 1998-10-15 Medivir Ab Inhibiteurs de proteases antiviraux
WO2000034241A1 (fr) * 1998-12-10 2000-06-15 Novartis Ag 2-cyanopyrrolidines n-substitues
WO2003029200A2 (fr) * 2001-10-02 2003-04-10 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles comme inhibiteurs reversibles de cysteine protease
WO2003045977A2 (fr) * 2001-11-26 2003-06-05 Trustees Of Tufts College Inhibiteurs peptidomimetiques d'enzymes de clivage post-proline

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHAKRABATTI J. ET AL: "Synthesis of N-(2-Chloroethyl) amides of Amino Acids as Potential Cytotoxic Agents", J. MED. CHEM., vol. 10, March 1967 (1967-03-01), pages 285 - 287, XP002324628 *
HOEL A.M.L ET AL.: "Microwave-Assisted Solid-Phase Ugi four-component Condensations", TERAHEDRON LETTERS, vol. 40, 1999, pages 3941 - 3944, XP002324627 *
RICH, D.H. ET AL: "Synthesis of Analogues of Pepstatin", J. MED. CHEM., vol. 26, 1983, pages 904 - 910, XP002324629 *
SENTEN, K. ET AL.: "Rapid Parallel Synthesis of Dipeptide Diphenyl Phosphonate Esters as Inhibitors of Dipeptidyl Peptidases", J. COMB. CHEM., vol. 5, no. 3, 2 April 2003 (2003-04-02), pages 336 - 344, XP002324626 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs

Also Published As

Publication number Publication date
PE20050948A1 (es) 2005-12-16
WO2005025554A2 (fr) 2005-03-24
AR046330A1 (es) 2005-12-07
TW200530157A (en) 2005-09-16

Similar Documents

Publication Publication Date Title
WO2005025554A3 (fr) Inhibiteur de la dipeptidylpeptidase iv
WO2003000180A3 (fr) Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete
WO2004037181A3 (fr) Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants
WO2003000181A3 (fr) Inhibiteurs de dipeptidyl peptidase utilises dans le traitement du diabete
WO2006071762A3 (fr) Inhibiteurs de dipeptidyl-peptidase iv a base de pyrimidine et methodes associees
EP1578414A4 (fr) Derives de phenylalanine utilises comme inhibiteurs de la dipeptidylpeptisase pour le traitement ou la prevention de diabetes
EP1583534A4 (fr) Derives de 3-amino-4-phenylbutanoique acide utilises en tant qu'inhibiteurs de dipeptidyl peptidase pour le traitement ou la prevention du diabete
AU2003286776A1 (en) Novel inhibitors of dipeptidyl peptidase iv
EP1592689A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
EP1589969A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
WO2006127287A3 (fr) Inhibiteurs a base de pyrrolopyridine, pour inhiber la dipeptidyl peptidase iv, et procedes correspondants
AU2003257822A1 (en) Heterocyclic compound having hiv integrase inhibitory activity
WO2008075068A3 (fr) Nouveaux composés
EP1756074A4 (fr) Derives de 1,2,4-oxadiazole en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le traitement ou la prevention de diabetes
PL1928499T3 (pl) Zastosowanie inhibitora DPP-IV do ograniczania epizodów hipoglikemii
HRP20130664T1 (en) Heterocyclic aspartyl protease inhibitors
EP1756106A4 (fr) Derives de la cyclohexylalanine utilises comme inhibiteurs de la dipeptidyl peptidase-iv pour le traitement ou la prevention des diabetes
TW200634018A (en) Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses
WO2006011631A3 (fr) Derives de thiazole presentant une activite d'inhibition de la vap-1
WO2004101528A3 (fr) Inhibiteurs de la gfat
WO2004026822A3 (fr) Compositions pharmaceutiques utiles comme inhibiteurs de la peptidase-iv dipeptidyl (dpp-iv)
WO2006065277A3 (fr) Inhibiteurs d'aspartyle protease heterocycliques
WO2005021544A3 (fr) Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
AU2003278088A1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
WO2005049022A3 (fr) Utilisation de composes organiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP